Dr. Grivas on Attempts to Improve Upon Chemotherapy in Urothelial Cancer

Video

In Partnership With:

Petros Grivas, MD, PhD, discusses attempts to improve upon chemotherapy as a therapeutic strategy in urothelial cancer.

Petros Grivas, MD, PhD, physician, Seattle Cancer Care Alliance, associate professor, Division of Medical Oncology, University of Washington (UW) School of Medicine, clinical director, Genitourinary Cancers Program, UW Medicine, associate member, Clinical Research Division, Fred Hutchinson Cancer Center, discusses attempts to improve upon chemotherapy as a therapeutic strategy in urothelial cancer.

The field of urothelial cancer continues to evolve with multiple attempts to improve upon chemotherapy alone in the frontline setting, Grivas says. Cisplatin-based chemotherapy has produced encouraging results with response rates of about 55%; however,improvement is needed, Grivas adds. Response rates with gemcitabine and carboplatin are about 40% to 45%, Grivas says. Historically, the median progression-free survival with chemotherapy in urothelial cancer has been between 7 and 8 months, whereas overall survival (OS) has been around 15 months, Grivas explains.

In recent years, studies, such as the phase 3 IMvigor130 (NCT02807636) and KEYNOTE-361 (NCT02853305) trials, have evaluated chemotherapy in combination with immunotherapy, Grivas says. IMvigor130 evaluated atezolizumab (Tecentriq) and KEYNOTE-361 evaluated pembrolizumab (Keytruda), both in combination with platinum-based chemotherapy for patients with urothelial carcinoma. However, both trials failed to demonstrate a statistically significant OS benefit with chemoimmunotherapy vs chemotherapy alone, Grivas concludes.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute